Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly.

Trial Profile

Phase I, Open Label Study of a DNA Vaccine's Ability to Increase the Immune Response to the Trivalent Seasonal Influenza Vaccine in the Elderly.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2015

At a glance

  • Drugs FVH 1 (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions
  • Most Recent Events

    • 16 Apr 2015 Status changed from active, no longer recruiting to completed, according to to ClinicalTrials.gov record.
    • 09 Dec 2014 Planned End Date changed from 1 Oct 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
    • 10 Dec 2012 Interim results from the last two treatment arms were presented in an Inovio Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top